Eales disease (ED) is a common, idiopathic, inflammatory retinal vasculitis that particularly affects young adults. Current treatments available for ED include corticosteroids, laser photocoagulation, retinal cryotherapy, and surgery, but a recent study found that using intravitreal bevacizumab injections may produce better outcomes and reduce the need for surgery.
Eales disease (ED) is a common, idiopathic, inflammatory retinal vasculitis that particularly affects young adults. The pathogenesis of ED is poorly understood, but some studies have attributed the disease to a response to Mycobacterium Tuberculosis antigens. The disease involves stages of retinal vasculitis, nonperfusion, neovascularization, vitreous hemorrhage (VH) and tractional retinal detachment (TRD).
Current treatments available for ED include corticosteroids, laser photocoagulation, retinal cryotherapy, and surgery, but a recent study, published in the Pakistan Journal of Medical Sciences, found that using intravitreal bevacizumab injections to treat ED may produce better outcomes and reduce the need for surgery.
The paper reports on a trial carried out at a single center from May 2015 to December 2016 in 26 patients—and 52 eyes—diagnosed with ED. Patients were randomized to receive either intravitreal bevacizumab injections or standard treatment with steroids and photocoagulation.
In the group that received bevacizumab, 9 eyes (24.6%) progressed to stage III or stage IV disease, while in the standard treatment group, 18 eyes (69.2%) progressed in disease severity. Six eyes in the bevacizumab group and 16 in the standard treatment group required surgery.
The groups showed comparable regression of vasculitis, but regression of neovascularization was observed more in the bevacizumab group (16 eyes) than the standard treatment group (6 eyes).
The difference in both groups in terms of final disease stage at 12 weeks was not statically significant (P = .066), though the number of eyes in stage I was 15 (58%) in the bevacizumab group versus 6 (23%) in the standard treatment group. “This shows considerably more number of eyes showing regression of ED,” write the authors.
The authors conclude that giving intravitreal bevacizumab injections monthly in patients with stage I or stage II ED results in more regression in vascularization and less need for surgery versus standard therapy, and it should be considered as an adjunct therapy to avoid progression of the disease.
Reference
Mehboob MA, Tahir M, Batool H. Role of intravitreal bevacizumab in management of Eale’s disease. Pak J Med Sci. 2018;34(2):333-337. doi: 10.12669/pjms.342.14483.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.